STAT June 4, 2024
Elaine Chen

Good morning. Today, FDA advisers are convening to discuss Lykos Therapeutics’ MDMA-assisted psychotherapy for people with PTSD. It’s a critical meeting — MDMA could be the first Schedule I psychedelic to be deemed to have a medical use. Our reporters Olivia Goldhill and Meghana Keshavan will be live-blogging the meeting all day — tune in here.

The need-to-know this morning

  • It’s a clinical trial readout kind of morning, starting with Viking Therapeutics and its MASH treatment, called VK2809, with mid-stage results.
  • BridgeBio Pharma reported long-term results from a study of its drug called infigratinib for the treatment of achondroplasia, a form of dwarfism.
  • Annexon Biosciences announced the outcome of a Phase 3 study in Guillain-Barré syndrome.

AZ’s CAR-T...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Clinical Trials, FDA, Govt Agencies, Mental Health, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Trends
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article